Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 72 Print this page  Email this page Small font size Default font size Increase font size
ORIGINAL ARTICLE
Year : 2021  |  Volume : 36  |  Issue : 2  |  Page : 107-113

Prognostic value of metabolic tumor parameters in pretreatment 18F-fluorodeoxyglucose positron emission tomography–computed tomography scan in advanced non-small cell lung cancer


1 Departments of Nuclear Medicine and PET-CT, Tata Medical Center, Kolkata, West Bengal, India
2 Departments of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

Correspondence Address:
Dr. Jayanta Das
Department of Nuclear Medicine and PET-CT, Tata Medical Center, Kolkata - 700 084, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijnm.IJNM_170_20

Rights and Permissions

Objective: This retrospective study aimed to investigate whether metabolic parameters of primary tumour i.e. maximum standardized uptake value (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) predict overall survival (OS) in patients with advanced stage non-small cell lung cancer (NSCLC). Materials and Methods: SUVmax, MTV and TLG of the primary tumors were measured in staging 18F-Fluorodeoxyglucose Positron emission tomography- Computed tomography (18F-FDG PET/CT) scan of 97 NSCLC patients by gradient based tumour segmentation method. Prognostic ability was assessed for overall survival (OS) of the patients. Result: The median follow-up period of the study was 15.84 months (range 1.3 to 47.97 months).The estimated median OS was 11.29 months (range 1.37 to 38.63 months). Total of 40 (41.24%) patients had progressive disease and 21 (21.65%) patients died during the follow up period. Receiver Operating Characteristic (ROC) analysis showed that the area under the curve (AUC) for MTV was significant (area = 0.652 ± 0.065; 95% CI = 0.548 – 0.746; P = 0.020). Kaplan-Meier survival curves showed that the OS differences between the groups of patients who were dichotomized by the median value of MTV (38.76 ml, P = 0.0150) and TLG (301.69 ml, P = 0.0046) were significant. MTV (hazard ratio = 4.524; 95% CI = 1.244 – 16.451; P = 0.022) was found to be an independent prognostic factor for OS in multivariate analysis. Conclusion: MTV of the primary tumor is a potential prognostic parameter for OS in our population of advanced NSCLC patients independent of other risk factors.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed924    
    Printed8    
    Emailed0    
    PDF Downloaded176    
    Comments [Add]    

Recommend this journal